As of June 27, 2023, Avalo Therapeutics (NASDAQ:AVTX) has experienced a significant downgrade from RBC Capital analyst Gregory Renza. The previous Outperform rating has now been lowered to Sector Perform, with the price target plummeting from $17 to a mere $0.75. This change is a far cry from the previous rating and target, which were both much higher at Outperform and $17, respectively.
Unfortunately, this is not the first downgrade for Avalo Therapeutics this year. Jefferies had previously downgraded the company from Hold to Underperform on February 8, 2023. However, Oppenheimer had adjusted the price target to $10 from $17, but maintained an Outperform rating on November 9, 2022.
Despite these setbacks, Cantor Fitzgerald initiated coverage on Avalo Therapeutics with an Overweight rating. The clinical stage biotechnology company is focused on developing therapies for immune dysregulation.
Avalo Therapeutics, Inc.
Updated on: 06/12/2023
Debt to equity ratio: Strong Sell
Price to earnings ratio: Neutral
Price to book ratio: Strong Sell
DCF: Strong Buy
ROE: Strong Buy
We did not find social sentiment data for this stock
There are no analysts data to display
AVTX Stock Analysis: Strong Earnings Growth and Good Financial Health
On June 27, 2023, AVTX stock opened at $0.76 and fluctuated between $0.50 and $0.87 with a trading volume of 29,578,615, and a market capitalization of $59.5M. AVTX had a strong earnings growth of 96.29% last year and is expected to have a growth of 25.73% this year. The P/E ratio and price/book ratio for AVTX are not available. AVTX’s price/sales ratio is 2.63, which is a good indication of the company’s financial health. AVTX stock performed poorly compared to other companies in the health technology sector on June 27, 2023. AVTX’s next reporting date is on August 10, 2023, and the EPS forecast for this quarter is -$0.80. AVTX operates in the pharmaceuticals: major industry and is headquartered in Rockville, Maryland.
Avalo Therapeutics Inc (AVTX) Stock Performance Soars, Analysts Predict 972% Increase in Median Target
On June 27, 2023, Avalo Therapeutics Inc (AVTX) showed a significant increase in stock performance. According to data from CNN Money, the 2 analysts offering 12-month price forecasts for the company have a median target of 5.38, with a high estimate of 10.00 and a low estimate of 0.75. The median estimate represents a +972.85% increase from the last price of 0.50. The current consensus among 2 polled investment analysts is to buy stock in Avalo Therapeutics Inc. This rating has held steady since June, when it was unchanged from a buy rating. Looking at the current quarter, Avalo Therapeutics Inc reported earnings per share of -$0.80 and sales of $1.0M. Investors should keep an eye on the company’s upcoming earnings report on August 10, 2023 to see how it continues to perform.